Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAMSA followed by T cell-depleted reduced-intensity allogeneic stem cell transplantation and donor lymphocyte infusion in older AML or high-risk MDS
NL-OMON22287Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of amsacrine, cytarabine, alemtuzumab, antithymocyte globulin rabbit and donor lymphocytes in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Eligibility for donor lymphocyte infusion at 6 months, Grade 3-4 non-hematological toxicity and 3 more. Started Jun 2013; status: recruiting.
02
Drugs
amsacrinecytarabinealemtuzumabantithymocyte globulin rabbitdonor lymphocytes
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON22287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22287.